Loading...
•
Sep 30, 2021
Kiniksa Q3 2021 Earnings Report
Reported third quarter financial results and recent portfolio execution.
Key Takeaways
Kiniksa Pharmaceuticals reported Q3 2021 financial results, highlighting ARCALYST's launch performance in recurrent pericarditis and progress in the clinical-stage pipeline, including mavrilimumab and vixarelimab.
ARCALYST net revenue was $12.1 million in Q3 2021.
More than 200 physicians have prescribed ARCALYST for recurrent pericarditis since approval.
Phase 3 trial data for mavrilimumab in COVID-19-related ARDS is expected in Q1 2022.
Phase 2b trial data for vixarelimab in prurigo nodularis is expected in 2H 2022.
Revenue by Segment
Forward Guidance
Kiniksa expects to initiate a Phase 2 proof-of-concept trial of KPL-404 in rheumatoid arthritis by the end of 2021 and anticipates continued commercial demand for ARCALYST.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...